Autopsy report · NCT04206917

MultiPulse Therapy (MPT) for AF

“Sponsor ceasing operations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 30 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Cardialen, Inc.

Sponsor type

Industry

Conditions

Atrial Fibrillation, Paroxysmal; Atrial Fibrillation, Persistent; Atrial Fibrillation

Interventions

Multi Pulse Therapy

Participants

30

Sites

6

Countries

Australia

Trials that died the same way

• Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
  “Sponsor strategy” (74% match in meaning)
• Long-term Registry of Patients Treated With Loncastuximab Tesirine
  “Sponsor administrative decision” (73% match in meaning)
• A Study of PY314 in Subjects With Advanced Solid Tumors
  “Sponsor business decision.” (73% match in meaning)
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  “sponsor decision (not for safety)” (71% match in meaning)
• Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
  “Sponsor decision (not due to safety concerns)” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.